CasNo： 2023788-19-2
Molecular Formula： C225H348N48O68
|
Description |
In November 2023, the FDA approved tirzepatide for weight loss in individuals without diabetes under the brand name Zepbound. It is the first medication in its class and is administered as a once-weekly injection. |
|
Uses |
Tirzepatide is an antidiabetic medication used for the treatment of type 2 diabetes and for weight loss. It is administered through subcutaneous injection and is sold under the brand name Mounjaro, among others. It works by impacting the body's insulin levels, blood glucose (sugar) production, and hunger hormones. |
Tirzepatide is a novel dual GIP/GLP-1 receptor agonist formulated as a synthetic peptide containing 39 amino acids, based on the native GIP sequence. Pre-clinical trials and phase 1 and 2 clinical trials indicate that tirzepatide has potent glucose lowering and weight loss with adverse effects comparable to those of established GLP-1 receptor agonists.
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist under development for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of tirzepatide versus titrated insulin degludec in people with type 2 diabetes inadequately controlled by metformin with or without SGLT2 inhibitors.